Cargo Shorts Therapeutics–Concentra Biosciences merger
Please read the SEC documents regarding this current security and understand that I do own of these shares. This isn’t an offer or solicitation to buy shares.
He’s really putting that attorneys kids through college. This one feels higher risk than usual.
• Cash Payment: Shareholders received $4.379 per share in cash.
• Contingent Value Right (CVR): Non-tradeable CVR includes:• 100% of net cash exceeding $217.5 million at closing.
• 80% of net proceeds from any sale or licensing of Cargo’s pipeline assets over two years.
• Pipeline includes:• Firicabtagene autoleucel (CD22 CAR-T) — suspended due to safety and efficacy concerns.
• Trispecific CAR-T (CRG-023) — targets CD19/20/22;
• Allogeneic CAR-T platform —
• Cash and Equivalents: $61.8 million
• Short-Term Marketable Securities: $257.1 million
• Total Liquid Assets: $318.9 million
All expressions of opinion reflect the judgment of the author and are subject to change. The information should not be construed as a recommendation. The foregoing content is subject to change at any time without notice content provided herein is for informational purposes only there is no guarantee these statements or forecasts will prove correct. past performance is no guarantee of future results. Investing involves risk including the possible loss of capital.